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DOI 10.1016/j.ccr.2010.03.020SUMMARYA hallmark feature of glioblastoma is its strong self-renewal potential and immature differentiation state,
which contributes to its plasticity and therapeutic resistance. Here, integrated genomic and biological
analyses identified PLAGL2 as a potent protooncogene targeted for amplification/gain in malignant gliomas.
Enhanced PLAGL2 expression strongly suppresses neural stem cell (NSC) and glioma-initiating cell differen-
tiation while promoting their self-renewal capacity upon differentiation induction. Transcriptome analysis
revealed that these differentiation-suppressive activities are attributable in part to PLAGL2 modulation of
Wnt/b-catenin signaling. Inhibition ofWnt signaling partially restores PLAGL2-expressing NSCdifferentiation
capacity. The identification of PLAGL2 as a glioma oncogene highlights the importance of a growing class of
cancer genes functioning to impart stem cell-like characteristics in malignant cells.INTRODUCTION
Malignant gliomas, the most common primary brain tumors in
adults, are associated with an extremely high rate of morbidity
and mortality (Furnari et al., 2007). In its most aggressive form,
glioblastoma (GBM) has an average survival of 1 year and char-
acteristic features of diffuse invasion, intense apoptosis resis-
tance and necrosis, robust angiogenesis, and a varied so-called
multiforme histological profile suggestive of developmental plas-
ticity. It is well known that malignant gliomas are heterogeneousSignificance
The identification of tumor-initiating cells with stem cell-like p
represents an important conceptual advance with therapeutic
of the molecular factors governing self-renewal and different
standing of glioma pathogenesis and biology. Such insights—
provide new points for therapeutic intervention. Here, the ide
with oncogenic activity and capacity to regulate Wnt signaling
genesis and points to differentiation pathways as promising taboth in their cell composition and in the relative abundance of
cells capable of propagating tumor cells, albeit the underlying
mechanism remains poorly understood (Furnari et al., 2007;
Rich and Eyler, 2008; Vescovi et al., 2006). The recent identifica-
tion of a subpopulation of tumor cells, designated as glioma stem
cell or glioma-initiating cells (GICs), with strong tumor repopulat-
ing potential has illuminated a potential basis for the intense
plasticity and heterogeneous nature of this disease (Bao et al.,
2006; Calabrese et al., 2007; Hemmati et al., 2003; Lee et al.,
2006; Piccirillo et al., 2006; Singh et al., 2004; Son et al., 2009).roperties in diverse cancers, including glioblastoma (GBM),
implications. There is increasing recognition that elucidation
iation of the glioma-initiating cells will advance our under-
at the intersection of stem cell and cancer biology—may
ntification of PLAGL2 as an amplified gene in human GBM
highlights the contribution of differentiation defect in glioma-
rgets for malignant glioma treatment.
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Figure 1. Genomic and Functional Charac-
terization of 20q11.21 Amplification in GBM
(A) Array CGH heat map detailing PLAGL2 amplifi-
cation at 20q11.21 in GBM tumor specimens and
cell lines. Regions of genomic amplification and
deletion are denoted in red and blue, respectively.
Mbs denote the position on chromosome 20 in
megabases.
(B) Schematic of the resident genes within minimal
common region of the 20q11.21 amplicon and the
chromosomal region spanned by the FISH probe
used in (C) are denoted.
(C) FISH of representative GBM specimen and cell
line using a probe within the amplified genomic
region labeled with FITC (green) and centromere
reference probe labeled with Cy3 (red).
(D) Quantification of soft agar colony formation of
the nine resident ORFs within the 20q11.21 ampli-
con in Ink4a/Arf /; Pten/ astrocytes. Data is
shown as mean ± SD from duplicate cultures of
three independent experiments. **p < 0.001 by
two-tail t test.
(E) PLAGL2 showed copy number-driven expres-
sion in the GBM specimen with 20q11.21 amplifi-
cation by qRT-PCR. Results are normalized with
b-actin expression and shown as mean ± SD.
Data are from two independent experiments with
triplicates. **p < 0.001 by two-tail t test. See also
Figure S1.
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(NSCs) including the expression of neural progenitor markers,
long term self-renewal capacity, and partial multi-lineage differ-
entiation potential. However, unlike the normal NSCs that follow
the developmental hierarchy and differentiate inevitably into
replication-arrested mature cells (Alvarez-Buylla et al., 2001;
Gage, 2000; Temple, 2001), the GICs exhibit anomalous devel-
opmental programs that enable escape from terminal differenti-
ation cues and preserve self-renewal state (Jackson et al., 2006;
Ricci-Vitiani et al., 2007; Sanai et al., 2005). Notably, restoration
of their differentiation capacities can drastically reduce GIC
tumorigenic potential, supporting the idea that maintenance of
an aberrant differentiation state can contribute to glioma patho-
genesis (Jackson et al., 2006; Lee et al., 2008; Ricci-Vitiani et al.,
2007; Zheng et al., 2008).
GBM possesses a highly rearranged genome. High-resolution
genome-scale analysis of such has uncovered myriad somatic
alterations on the genomic and epigenetic levels, which presum-
ably harbor GBM-related oncogenes or tumor suppressors.
To identify these events, we previously had performed high
resolution, oligo-based array comparative genomic hybridization
(CGH) profiling of 18 pathologically verified primary GBM
specimens and 20 established glioma cell lines (Wiedemeyer
et al., 2008). Using the nonheuristic genome topography scan
(GTS) algorithm, we further identified and ranked the signature
genomic events known previously for GBM (e.g., EGFR amplifi-
cation or CDKN2A deletion) as well as many previously unchar-
acterized alterations based on their amplitude, width, and recur-
rence of a copy number alteration (Wiedemeyer et al., 2008).
Here we carried an in-depth study on one of the uncharacterized498 Cancer Cell 17, 497–509, May 18, 2010 ª2010 Elsevier Inc.amplified/gained regions that is localized at chromosome
20q11.21.
RESULTS
PLAGL2 Is Targeted for Amplification and
Overexpression
GTS analysis of the array CGH profiles of 18 pathologically
verified primary GBM specimens and 20 glioma cell lines identi-
fied chromosome 20q11.21 as a region of amplification or gain
(Figure 1A; Wiedemeyer et al., 2008). These profiles delimited
a 500 Kb minimal common region of amplification encompassing
seven characterized genes (HCK, TM9SF4, TSPYL3, PLAGL2,
POFUT1, ASXL1, and KIF3B), two conserved open reading
frames (ORFs) (c20orf120 and c20orf112), and one pseudogene
(RPL24P1) (Figure 1B). Regional amplifications/gains were
further confirmed in the primary tumor (#G328) and cell lines
(LN229) by fluorescence in situ hybridization (FISH) using a probe
within the 20q11.21 amplicon (Figure 1C). Subsequent analysis
of the TCGA data confirmed increased copy number of a broad
region at 20q11.21 in 35 of 238 (14.7%) human GBM array
CGH profiles (http://tcga-data.nci.nih.gov/tcga/findArchives.htm).
The potential cancer relevance of this region was further sug-
gested by its amplification/gain in approximately 40% of primary
colorectal cancer specimens and cells lines (Figure S1, available
online; Martin et al., 2007).
To determine the oncogenic potential of all nine genes residing
within this amplicon, we first assessed their ability to promote
anchorage-independent growth. In these studies, we used freshly
isolated primary murine astrocytes doubly null for Ink4a/Arf and
Figure 2. PLAGL2 Promotes Cellular Trans-
formation and Invasion
(A) Ectopic PLAGL2 expression enhanced
anchorage-independent growth in human glioma
LN215 cells.
(B) PLAGL2 expression in LN215 cells promoted
cell invasion through matrix protein in a Boyden
chamber. Representative images of invasion
assay showing empty vector control and
PLAGL2-expressing LN215 cells after 16 hr induc-
tion with 10% FBS followed by crystal violet (0.2%)
staining.
(C) Quantification of (B).
(D) Knockdown of PLAGL2 expression in LN340
and U87 glioma cells decreased soft agar colony
formation.
(E) Efficiency of PLAGL2 knockdown using
shRNAs in (D).
(F) Knockdown of PLAGL2 expression in LN319
glioma cells resulted in modest effect on its colony
formation activity. The PLAGL2 knockdown effi-
ciencies in (E) and (F) were measured by qRT-PCR and are presented here after normalization with b-actin expression. Data shown in (A)–(F) are the mean ±
SD from at least two independent experiments with triplicates. *p < 0.001, **p < 0.005, and ***p < 0.01. See also Figure S2.
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PLAGL2 Regulates NSC and Glioma DifferentiationPten, two signature mutations present in human primary GBM
(Cancer Genomes Atlas Research Network, 2008; Parsons
et al., 2008). Notably, these Ink4a/Arf/ Pten/ astrocytes do
not exhibit anchorage-independent growth unless transduced
with additional oncogenes such as the mutant epidermal growth
factor receptor EGFRvIII (data not shown). In this ‘‘sensitized’’
glioma-relevant background, the above nine ORFs were placed
in the pLenti6-V5-DEST expression vector and introduced indi-
vidually into the Ink4a/Arf / Pten / astrocytes. Of the nine
cancer gene candidates, only PLAGL2 induced colony formation
in the semisolid media (Figure 1D). Consistent with PLAGL2 as the
target in this amplicon, quantitative real-time reverse transcrip-
tase PCR (qRT-PCR) revealed that PLAGL2 showed gene copy
number-driven expression in the primary GBM specimen
(#G328) with the 20q11.21 amplification (Figure 1E). Together,
these data suggest that PLAGL2 functions as an oncogene that
is targeted for amplification/gain and overexpression in a subset
of human GBM and colorectal cancer cases.
PLAGL2 Promotes Cell Transformation In Vitro
and Tumorigenesis In Vivo
PLAGL2 (pleiomorphic adenoma gene like 2), a putative C2H2
zinc finger transcription factor, was initially identified through
structural homology to its family member PLAG1, a protoonco-
gene frequently rearranged and overexpressed in pleiomorphic
salivary gland adenomas and lipoblastomas (Hensen et al.,
2002; Kas et al., 1997, 1998). Aberrant PLAGL2 expression has
recently been implicated in human acute myeloid leukemia
(Landrette et al., 2005). However, the biological functions of
PLAGL2, including whether and how it is involved in tumorigen-
esis, still remain largely unknown. To substantiate the cancer
relevance of PLAGL2, we assayed the oncogenic activity of
PLAGL2 in several cell-based systems using both gain- and
loss-of-function strategies. Consistent with the murine Ink4a/
Arf/ Pten/ astrocytes findings, enforced PLAGL2 expres-
sion also conferred markedly increased anchorage-independent
growth of murine p53/ astrocytes (Figure S2A) and human
glioma cell lines including LN215, A172, Hs683, LNZ308,SF767, and U343 (Figure 2A and Figure S2A). In addition, we as-
sessed the impact of PLAGL2 on invasive activity, a hallmark
feature of malignant gliomas (Furnari et al., 2007). Using the
modified Boyden chamber assay, enforced PLAGL2 expression
in both human LN215 cells (Figures 2B and 2C) and primary
murine Ink4a/Arf/ Pten/ as well as p53/ astrocytes (Fig-
ures S2B and S2C) significantly enhanced their invasive capacity
through matrigel. Conversely, shRNA-mediated suppression of
PLAGL2 reduced anchorage-independent growth of LN340
and U87 cells—two glioma lines with 20q11.21 amplification
and relatively high PLAGL2 expression levels (Figures 2D and
2E). Of note, suppressing PLAGL2 expression in the LN319
glioma line lacking 20q11.21 amplification and with low PLAGL2
expression failed to impact on anchorage-independent growth
(Figure 2F), suggesting that PLAGL2 may serve a tumor mainte-
nance role in those gliomas with PLAGL2 gene amplification and
high expression.
In line with the colorectal cancer genomic observation,
PLAGL2-expressing immortalized rat intestinal epithelial cells
(IEC6) exhibited oncogenic properties of (a) growth in an
anchorage-independent manner (Figure S2D), (b) anoikis resis-
tance on ultra-low cluster plates (Figure S2E), and (c) robust
tumor growth with metastatic potential within 5 weeks after tail
vein injection. In contrast, IEC6 vector control cells failed to
produce illness within 3 months of observation (Figure S2F).
On the basis of these functional studies, we conclude that
PLAGL2 is a potent oncogene that is targeted for amplifica-
tion/gain in a subset of colorectal cancers.
PLAGL2 Promotes Renewal of NSC/Progenitor Cells
by Inhibiting Their Differentiation
While enforced PLAGL2 expression in human LN215 glioma cells
or primary mouse Ink4a/Arf/ Pten/ astrocytes had a notably
minimal impact on cellular proliferation, these cells adopted a
rounded, less attached, refractile appearance reminiscent of
stem/progenitor cells (Figure S3). Correspondingly, these
PLAGL2-expressing LN215 cells showed increased expression
of the neural stem/progenitor marker Nestin (Figure S3C). TheseCancer Cell 17, 497–509, May 18, 2010 ª2010 Elsevier Inc. 499
Figure 3. PlagL2 Promotes NSC/Progenitor
Cell Proliferation by Attenuating Its Differ-
entiation
(A) The multi-linage differentiation induced by FBS
was markedly diminished in PlagL2-expressing
p53/ NSCs. Representative immunofluores-
cence staining of empty vector control and
PlagL2-expressing NSCs cultured in the presence
of 1% FBS (without EGF and bFGF) for 5 days.
(B) Histograms show the percentage of Nestin-,
GFAP-, and Tuj1-positive cells after 1% FBS
induction in (A).
(C) PlagL2 sustained NSC proliferation under
differentiation induction. Representative immu-
nostaining of empty vector control and PlagL2-
expressing p53/ NSCs cultured for 5 days in
1% FBS (without EGF and bFGF) and labeled
with BrdU (10 mg/ml) for either 3 or 24 hr, respec-
tively.
(D) Quantification of the BrdU-positive cells in (C).
Data shown in (B) and (D) are the mean ± SD.
Results are representative of three independent
experiments. *p < 0.001 and **p < 0.01 by two-
tail t test. Scale bars represent 50 mm. See also
Figure S3.
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oncogenic impact in part via promoting a stem/progenitor cell-
like state. To test this hypothesis, we first used murine p53/
NSCs as a model system as it affords a primary cell system
and allows for analysis in the context of p53 mutation, one of
the most frequent alterations in human primary GBM (Cancer
Genomes Atlas Research Network, 2008; Parsons et al., 2008).
This p53/ NSC model system (and confirmatory studies in
wild-type as well as Ink4a/Arf/ Pten/ NSCs) was used to
explore PLAGL2-directed cellular and molecular activities analo-
gous to those of our previous studies (Zheng et al., 2008).
When maintained in the serum-free NSC proliferation media
supplemented with growth factors EGF and bFGF, both vector
control and PlagL2-expressing cells registered roughly the
same NSC/progenitor cell marker patterns such as Nestin
expression and showed minimal differences in proliferation as
measured by BrdU incorporation rate (data not shown). Upon
exposure to differentiation media (neural basal media with 1%
fetal bovine serum), as expected, the p53/ NSC vector control
cultures rapidly adopted a flattened cell morphology, drastically
diminished Nestin expression, and reciprocally increased GFAP
(astrocytic marker) or Tuj1 (early neuronal lineage marker) posi-
tive staining. In contrast, PlagL2-expressing p53/ NSCs
retained their stem/progenitor-like morphology and showed
feeble expression of mature lineage markers; 70% of PlagL2-
expressing cells retained Nestin expression compared with 5%
of control cells (Figures 3A and 3B). Additionally, we failed to
observe cell-cycle exit that accompanies differentiation in the
PlagL2-expressing cells as evidenced by their robust BrdU
incorporation following either a 3 or 24 hr BrdU pulse (3 hr: 1.6 ±
1.1% versus 15.6 ± 5.0%; 24 hr: 1.5 ± 1.6% versus 84.0 ± 6.6%)
(Figure 3C, p < 0.001). Similar results were also observed using500 Cancer Cell 17, 497–509, May 18, 2010 ª2010 Elsevier Inc.wild-type and Ink4a/Arf/ Pten/ mouse NSC cultures (Fig-
ures S4A and S4B).
To confirm further the impaired differentiation phenotype, we
used additional differentiation protocols. We first used the
bone morphogenetic protein (BMP)-mediated differentiation
assay, which is known for its function to activate SMAD1/5/8
and elicit astroglial differentiation of NSC cultures (Lim et al.,
2000; Panchision and McKay, 2002). As expected, BMP2 treat-
ment arrested cell proliferation and stimulated rapid differentia-
tion of the majority of vector control p53/ NSCs (77%–80%)
into GFAP- and S-100-positive astroglial lineage cells (Figures
4A and 4B); in contrast, over 70% of PlagL2-expressing NSCs
retained strong Nestin expression and showed minimal increase
of GFAP- and S-100-positive cells. Accordingly, compared to
4% of vector control cells, which incorporated BrdU following
BMP treatment, 61% of PlagL2-expressing cells were stained
for BrdU (Figure 4C). Analogous differentiation findings were
obtained for p53/ NSC cultures maintained in neural basal
media without growth factors (Figure S4C). In addition, we con-
firmed that BMP2 induced strong activation of SMAD1/5/8 com-
ponents in both vector control and PlagL2-expressing NSCs
(Figure 4D), indicating the impaired differentiation phenotype is
not attributable to suboptimal activation of the BMP signaling
pathway in the PlagL2-expressing NSCs.
Progressive differentiation of normal stem/progenitor cells is
associated with loss of self-renewal capacity, while cancer cells
with high tumorigenic potential typically exhibit strong self-
renewal activity with impaired differentiation (Beachy et al.,
2004; Buick et al., 1979; Dick, 2008; Reya et al., 2001; Sanai
et al., 2005). We thus tested whether PlagL2 also affects NSC
self-renewal activity as measured by neurosphere formation.
When cultured at low density (100 cells/ml) in the NSC
Figure 4. PlagL2 Blocks BMP2-Mediated
Differentiation and Maintains NSC/Progen-
itor Proliferation and Self-Renewal
(A) BMP2-mediated astroglial differentiation was
abrogated in PlagL2-expressing p53/ NSCs.
Representative immunofluorescence staining of
empty vector control and PlagL2-expressing
NSCs cultured in the presence of BMP2 (50 ng/ml)
for 5 days with EGF (20 ng/ml) and bFGF (10 ng/ml)
and labeled with BrdU (10 mg/ml) for 3 hr. Nes,
nestin; Tuj, Tuj1; D, DAPI. Scale bars represent
50 mm.
(B) Histograms show the percentage of the
Nestin-, GFAP-, and Tuj1-positive cells after
BMP2 treatment in (A).
(C) Quantification of the BrdU-positive cells in (A).
Data shown in (B) and (C) are the mean ± SEM.
Results are representative of three independent
experiments with triplicate cultures. *p < 0.001
by two-tail t test.
(D) Western blot analysis of pSmad1/5/8 in empty
vector control and PlagL2-expressing p53/
NSCs. Cells were stimulated with BMP2 (50 ng/ml)
for 10 and 60 min. pSmad1/5/8 and Smad1
indicated serine phosphorylated Smad and
total Smad levels, respectively. HA denotes
HA-PlagL2.
(E) PlagL2 preserved NSC self-renewal under
BMP2 treatment. A total of 200 empty vector
control or PlagL2-expressing p53/ NSCs were
cultured in 6 well ultra-low attachment plates for
10 days in the presence of BMP2 (50 ng/ml),
EGF (20 ng/ml), and bFGF (10 ng/ml). (Top) Repre-
sentative images of neurospheres formed;
(Bottom) quantification of the neurosphere forma-
tion assays. Data shown in (E) are mean ± SEM
from two independent experiments with duplicate
cultures. *p < 0.001 by two-tail t test. See also
Figure S4.
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p53/NSCs yielded only slightly more multipotent neurospheres
(17.0 ± 3.7% for PLAGL2-expressing NSCs versus 13.8 ± 3.1%
for vector control NSCs; p = 0.032) and modestly higher prolifer-
ation rates to those of control p53/ NSCs (data not shown).
Following BMP2 treatment, while less than 1% of vector control
p53/ NSCs formed neurospheres, PlagL2-expressing p53/
NSCs readily formed neurospheres (0.65 ± 0.7% versus 12.8 ±
4.1%; p < 0.001) (Figure 4E). Together, these data establish that
enforced PlagL2 expression impedes NSC differentiation and
preserves their stem cell features such as self-renewal potential
and proliferation under differentiation induction.
PLAGL2 Promotes Gliomagenesis and Maintenance
of GIC ‘‘Stemness’’ upon Differentiation
The impact of PLAGL2 on NSC renewal and differentiation,
coupled with its transforming activity on primary astrocytes asCancer Cell 17, 497–5well as immortalized intestinal epithelial
cells, prompted us to assess whether
PLAGL2 influences the stem cell-like
properties of human glioma cells. These
stem-like properties are thought to residein the GIC subpopulation, which manifest by their self-renewal,
partial multi-lineage differentiation capacities, and superior
tumorigenic potential in orthotopic models (Bao et al., 2006;
Lee et al., 2006; Piccirillo et al., 2006; Singh et al., 2004; Son
et al., 2009). To assess such properties, we used early passage,
patient-derived GICs that, under serum-free conditions, retain
phenotypes and genotypes more closely mirroring primary
tumor profiles as compared to serum-cultured established
glioma cell lines that have largely lost their developmental
identities (Galli et al., 2004; Lee et al., 2006; Pollard et al., 2009).
Using the GIC model system, we observed that PLAGL2-
transduced GICs (PLAGL2 GBM-1) versus vector-transduced
GICs (control GBM-1) displayed a 4.3-fold increase (8.11%
versus 1.89%) of CD133-positive subpopulation; CD133 is a
surface progenitor marker associated with human GICs (Bao
et al., 2006; Lee et al., 2006; Piccirillo et al., 2006; Singh et al.,
2004) (Figure 5A and Figure S5A). Similar results were obtained09, May 18, 2010 ª2010 Elsevier Inc. 501
Figure 5. PLAGL2 Modulates GIC Differentiation State and Promotes Gliomagenesis
(A) FACS analysis of CD133-staining empty vector control (green) versus PLAGL2-expressing GBM-1 cells (red) cultured in the NSC proliferation medium with
EGF and bFGF.
(B) PLAGL2 attenuated GIC differentiation and sustained their proliferation. Representative immunostaining of empty vector control and PLAGL2-expressing
GBM-1 cells cultured in the presence of 2% FBS (without EGF and bFGF) and labeled with BrdU (10 mg/ml) for 3 hr. BF, bright-field; N, nestin; T, Tuj1;
G, GFAP; D, DAPI.
(C) Quantification of the BrdU-positive cells in (B). Data is shown as mean ± SD, representative of three independent experiments with duplicate cultures.
*p = 0.003 by two-tail t test.
(D) Overexpression of PLAGL2 promoted gliomagenesis. Survival of animals intracranially grafted with empty vector control (n = 6) and PLAGL2-expressing (n = 8)
GBM-1 cells. *p < 0.001 by log rank test.
(E) PLAGL2 promoted glioma cell invasion. Representative H&E staining of early tumors derived from empty vector control and PLAGL2-expressing GBM-1 cells
at 50 days. Scale bars represent 50 mm.
(F) Reduction of PLAGL2 expression through shRNA in GICs represses their tumorigenic potency. Survival of animals injected with GBM-3 cells infected with
shGFP, shPL-1, or shPL-2 (n = 6 for each). *p < 0.001 by log rank test. See also Figure S5.
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Figure 6. PlagL2 Activates Wnt/b-Catenin
Pathway in NSC/Progenitor Cells
(A) Ingenuity pathway analysis of PlagL2-directed
transcriptome showed enrichment of the canon-
ical Wnt/b-catenin pathways.
(B) Wnt6, Fzd2, and Fzd9 were significantly
upregulated in the PlagL2-expressing p53/
NSCs quantified by qRT-PCR. Data are shown
as mean ± SD after normalization with b-actin
expression. The results are from triplicates of
two independent experiments. *p < 0.005 and
p** < 0.001 by two-tail t test.
(C) PlagL2 upregulated b-catenin levels in NSCs
upon differentiation. Representative immunostain-
ing against b-catenin of empty vector control and
PlagL2-expressing NSCs cultured for 24 hr in the
presence of 1% FBS (without EGF and bFGF).
Scale bar represents 50 mm.
(D) Immunohistochemical staining of H&E and
b-catenin of control (G199) and PLAGL2 amplified
(G328) human GBM specimens. Scale bars repre-
sent 50 mm.
(E) TCF reporter activity was assessed using the b-catenin-responsive TOPflash reporter in empty vector control and PlagL2-expressing p53/ NSCs. Data
shown is mean ± SD from two independent experiments with triplicates. *p < 0.001 by two-tail t test. See also Figure S6.
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S5B). When cultured under differentiation-inducing conditions,
PLAGL2-expressing GICs retained robust Nestin expression
and substantially higher cell proliferation relative to the control
cells as measured by a 1 hr BrdU incorporation assay (6.8 ±
2.5% versus 23.7 ± 6.7%; p = 0.003) (Figures 5B and 5C).
Moreover, the in vivo tumorigenic assay indicated that the
PLAGL2-GICs (GBM-1) displayed enhanced tumorigenic poten-
tial. Compared to the control mice grafted intracranially with
5000 vector control GBM-1 that survived about 4 to 5 months
(Figure 5D), the mice injected with PLAGL2-GBM-1 often devel-
oped diffusively infiltrating gliomas within 2 to 3 months and died
at a median of 13.2 weeks. Notably, when examined at early
time points after implantation, unlike vector control GICs that
generated well circumscribed lesions with a clear boundary,
the PLAGL2-GIC tumors were substantially more invasive with
diffusively infiltrating tumor cells in the surrounding brain paren-
chyma (Figure 5E). These in vivo findings are consistent with the
above in vitro Boyden chamber assay indicating that high
PLAGL2 expression promotes glioma cell invasion. Conversely,
shRNA-mediated silencing of endogenous PLAGL2 expression
in a human GIC line (GBM-3) with relatively higher PLAGL2
expression substantially decreased its in vivo tumorigenicity
(Figure 5F and Figure S5C). Together, these findings support
the hypothesis that PLAGL2 functions to maintain stemness of
the GICs in the context of differentiation cues and enhances their
tumorigenicity and cellular invasion potential.
PLAGL2 Activates Wnt/b-Catenin Pathway
in NSC/Progenitor Cells
PLAGL2 is a Zinc finger transcription factor localized in the
nucleus (Kas et al., 1998). In an attempt to elucidate the molec-
ular mechanisms underlying PlagL2’s impact on murine p53/
NSC and human GIC differentiation, we performed transcrip-
tome comparisons of PlagL2-transduced and vector control
p53/ NSCs following the differentiation induction. As early as
24 hr after induction, approximately 400 genes exhibited signifi-cant differential expression. Ingenuity pathway analysis of the
PlagL2-directed transcriptome identified ‘‘cell-cycle G1/S
checkpoint control’’ as the most enriched canonical pathway
(Figure 6A), consistent with the higher proliferation observed in
the PlagL2-expressing NSCs and GICs under differentiation
induction. Notably, the Wnt/b-catenin cascade emerged as the
second most enriched canonical pathway. qRT-PCR further
confirmed that mRNA transcripts of multiple Wnt pathway
components, including the Wnt6 ligand and Fzd9 and Fzd2
receptors, were substantially upregulated in PlagL2-expressing
NSCs (Figure 6B). Consistently, upregulation of Wnt6, Fzd9,
and Fzd2 was also observed in PlagL2-expressing astrocytes
as well as the primary GBM clinical sample (G328) with PLAGL2
amplification (Figures S6A and S6B).
Wnt/b-catenin signaling plays an important role in maintaining
stem cells of various lineages including NSC/progenitor cells,
and aberrant activation of the Wnt/b-catenin pathway leads
to deregulated growth and cancer (Chenn and Walsh, 2002;
Clevers, 2006; Kalani et al., 2008). Thus, our unbiased
genome-scale analysis and confirmatory findings raised the
possibility that PlagL2’s function of suppressing NSC/progenitor
cell differentiation might be mediated in part through activation
of the Wnt/b-catenin pathway. A large body of previous work
has established that the canonical Wnt signaling pathway
executes its actions through the regulated degradation of the
transcriptional coactivator b-catenin (Clevers, 2006; He et al.,
2004; Logan and Nusse, 2004). In the absence of Wnt stimula-
tion, b-catenin is phosphorylated by GSK3 within the Axin
complex and then targeted for rapid degradation by the protea-
some (Aberle et al., 1997; Amit et al., 2002; Liu et al., 2002). On
the contrary, stimulation by Wnt inhibits b-catenin phosphoryla-
tion and promotes stability.
Consistent with PlagL2-induced activation of Wnt receptors
and ligands in NSC/progenitor cells, immunofluorescence stain-
ing revealed a significantly increased b-catenin accumulation
within the PlagL2-NSC/progenitor cells as compared to the
vector control cells (Figure 6C). In parallel, immunohistochemistryCancer Cell 17, 497–509, May 18, 2010 ª2010 Elsevier Inc. 503
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glioma patient samples with PLAGL2 amplification (Figure 6D)
and the orthotopic transplants of PLAGL2-GICs (Figure S6C),
reinforcing the role of PLAGL2 on Wnt/b-catenin pathway activa-
tion. Moreover, introduction of PlagL2 into murine NSC/progen-
itor cells and astrocytes enhanced their TCF-dependent
TOPflash reporter activity (Figure 6E and Figure S6D). Similar
results were observed using HEK293T and human glioma
LN215 cells (Figures S6E and S6F). Collectively, these data
indicate that PLAGL2 can activate the canonical Wnt/b-catenin
signaling cascade.
Inhibition ofWnt Signaling Attenuates PLAGL2’s Activity
on NSC/Progenitor Cell Differentiation
Numerous studies have documented the importance of Wnt
proteins and its canonical signaling surrogates in the mainte-
nance of stem cells in different tissues (Adachi et al., 2007;
Chenn and Walsh, 2002; Grigoryan et al., 2008; Nusse, 2008;
Pinto and Clevers, 2005; Zechner et al., 2003). Aberrant activa-
tion of Wnt/b-catenin signaling tips the homeostatic balance
toward pathological states including malignant transformation.
Consistently, we found that introduction of a stabilized form of
b-catenin into the mouse p53/ NSC/progenitor cells attenu-
ates their differentiation capacity while enhancing proliferation
(Figure S7A). This established paradigm, coupled with the above
genomic analysis, prompted us to test whether PlagL2 acts
through the Wnt/b-catenin pathway to maintain the progenitor
state of normal and neoplastic stem cells under differentiation-
inducing conditions.
We first investigated whether suppression of Wnt/b-catenin
signaling through Dickkopf-1 (DKK1) can attenuate PlagL2’s
function on NSC/progenitor differentiation. DKK1 is a secreted
Wnt inhibitor, which functions through direct binding to the Wnt
coreceptor Lrp5/6 and thus disrupts Wnt-induced canonical
Wnt/b-catenin pathway activation (Mao et al., 2001; Semenov
et al., 2001). Since our data indicated that PlagL2 activates
Wnt/b-catenin cascade on upstream signaling events through
upregulating ligand and receptor expression, one would predict
that introduction of DKK1 should suppress PlagL2-mediated
Wnt pathway activation. Indeed, while enforced PlagL2 expres-
sion in NSC/progenitor cells significantly increased the TOPflash
reporter activities as compared to the control cells, further
cotransfection with DKK1 largely reversed the stimulatory effect
of PlagL2 on the reporter activity (Figures 7A). Moreover, intro-
duction of DKK1 into PlagL2-expressing NSC/progenitor cells
partially restored their differentiation potential as demonstrated
by the decreased progenitor marker (Nestin) staining, increased
lineage marker (GFAP/Tuj1) expression, and reduced cell prolif-
eration (Figures 7B and 7C). Similar results were obtained when
shRNAs against Wnt6 or Fzd2 were introduced into PlagL2-
expressing NSC/progenitor cells (Figures 7D and 7E and
Figure S7B).
DISCUSSION
Cancers arise from disturbances of critical cellular functions
impacting self-renewal, differentiation, survival, and proliferation
(Al-Hajj and Clarke, 2004; Hanahan and Weinberg, 2000; Reya
et al., 2001) and such disturbances are often driven by genomic504 Cancer Cell 17, 497–509, May 18, 2010 ª2010 Elsevier Inc.aberrations in cancer cells. In the current study, integrative
genomic and functional analyses led to the identification and
validation of PLAGL2 as a potent oncoprotein frequently tar-
geted for copy number gain/amplification in human malignant
gliomas and colon cancers. Using both normal and neoplastic
NSC/progenitor cells as model systems, we demonstrated that
ectopic PLAGL2 expression greatly enhances NSC/progenitor
cell self-renewal and proliferation upon differentiation induction,
suggesting that PLAGL2 executes its oncogenic activities
through regulating the state of cellular differentiation. Addition-
ally, we have provided evidence that this function of PLAGL2
is at least partially attributable to its capacity to activate
Wnt/b-catenin signaling.
It has become increasingly clear that many cancers are
heterogeneous, reminiscent of normal tissue renewal with stem
cells at the apex of this hierarchy. The identification of clono-
genic tumor-initiating cells with stem-like features across many
different tumor types has supported the existence of a cellular
hierarchy in tumors (Al-Hajj et al., 2003; Bonnet and Dick,
1997; Hemmati et al., 2003; O’Brien et al., 2007; Ricci-Vitiani
et al., 2007; Singh et al., 2004; Taylor et al., 2005). These
tumor-initiating cells represent a reservoir of self-sustaining cells
with potent proliferative activity, differentiation resistance, and
tumorigenic potential (Clarke et al., 2006; Dick, 2008; Gilbertson
and Rich, 2007; Reya et al., 2001). Therefore, a relative arrest in
differentiation, such as seen in the PLAGL2-overexpressing
GICs, could contribute to malignant glioma progression through
maintenance and expansion of the GIC pool under conditions
that would otherwise lead to their differentiation. Alternatively,
the differentiation-resistant state promoted by elevated PLAGL2
expression could potentially lead to the accrual of self-renewing
glioma cells in which cell proliferation and differentiation are
uncoupled and therefore will allow a plurality of glioma cells to
assume indefinite proliferative capacity as suggested by the
‘‘blocked differentiation’’ model of cancer (Buick et al., 1979).
Support for this view derives from the observations that PLAGL2
overexpression leads to decreased astroglial differentiation,
enhanced renewal in NSCs under differentiation induction
conditions, increased CD133+ subpopulations, and enhanced
GIC tumorigenicity in vivo.
We provide further evidence that enhanced PLAGL2 expres-
sion contributes to the progression of a subset of human malig-
nant gliomas through regulating their differentiation and renewal.
Unlike normal NSCs that undergo progressive differentiation
along a developmental hierarchy into lineage-restricted progen-
itors and then their mature progenies (Alvarez-Buylla et al., 2001;
Gage, 2000; Temple, 2001), human malignant glioma cells
generally show minimal terminal differentiation traits and instead
exhibit robust expression of progenitor markers such as Nestin
(Tohyama et al., 1992). Furthermore, the self-renewal capacity
of the isolated GICs tends to correlate with their tumor grade
(Singh et al., 2003), supporting the idea that ‘‘differentiation
arrest’’ represents a common feature of malignant glioma pro-
gression. Like PLAGL2, some oncogenes can function to inter-
fere with normal stem cell differentiation, MYC being a notable
example, and such oncogenes also affect glioma cell differenti-
ation (Ben-Porath et al., 2008; Bruggeman et al., 2007; Molofsky
et al., 2003; Shachaf et al., 2004). However, PLAGL2’s function
on differentiation does not appear to use the MYC axis as
Figure 7. Inhibition of Wnt Signaling
Sensitizes PlagL2-Expressing NSCs to
Differentiation
(A) DKK1 attenuated PlagL2-induced Wnt
signaling activation. Vector control or DKK1
constructs were cotransfected with the TOPflash
reporter construct into vector control or PlagL2-
expressing p53/ NSCs. Forty-eight hours after
transfection and culture in NSC proliferation
medium with EGF (20 ng/ml) and bFGF (10 ng/ml),
the cells were transferred to culture in the pres-
ence of 1% FBS (without EGF and bFGF) and
TOPflash assays were performed. Data shown
are mean ± SEM from two independent experi-
ments performed in triplicate. *p < 0.001 and
**p < 0.01 by two-tail t test.
(B) DKK1 reduced PlagL2’s activity on NSC differ-
entiation. Representative immunofluorescence
staining of vector, DKK1/vector, PlagL2-express-
ing, and DKK1/PlagL2-expressing p53/ NSCs
cultured in the presence of 1% FBS (without EGF
and bFGF) for 5 days and labeled with BrdU
(10 mg/ml) for 3 hr. Nes, nestin; Tuj, Tuj1; D,
DAPI. Scale bars represent 50 mm.
(C) Quantification of the percentage of the Nestin-,
GFAP-, Tuj1-, and BrdU-positive cells in (B).
Data shown are mean ± SEM from two indepen-
dent experiments with duplicate. **p < 0.01 and
***p = 0.016 by two-tail t test.
(D) Wnt6 and Fzd2 knockdown partially restored
differentiation of PlagL2-expressing NSCs. Repre-
sentative immunofluorescence images from
empty vector or PlagL2-expressing p53/ NSCs
infected with control (shGFP) or shRNA against
Wnt6 and Fzd2 lentivirus. The cells were immuno-
stained with the indicated antibodies after culture
in differentiation medium (neural basal media +
1% FBS, without EGF and bFGF) for 5 days and
labeling with BrdU (10 mg/ml) for 3 hr.
(E) Quantification of the percentage of BrdU-posi-
tive cells in (D). Data were shown as mean ± SD
from two independent experiments with duplicate
cultures. See also Figure S7.
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expression (data not shown), suggesting that multiple pathways
can be commandeered to sustain self-renewal of GICs in the
face of differentiation cues. Consistent with this notion, the
BMP-BMPR signaling system that controls the activity of normal
brain stem cells can function as a key inhibitory regulator of GICs
by regulating their differentiation status (Bao et al., 2006; Calabr-
ese et al., 2007; Hemmati et al., 2003; Lee et al., 2006; Piccirillo
et al., 2006; Singh et al., 2004; Son et al., 2009). For example,
dysregulated BMP pathway with epigenetically silenced BMP
receptor 1B (BMPR1B) expression has been demonstrated to
contribute to the tumorigenicity of a subset of malignant gliomas
through blocking their GIC differentiation (Lee et al., 2008).
Forced BMPR1B expression in these GICs restored their differ-
entiation potential and substantially decreased their tumorigenic
potential, reinforcing further the view that targeting these differ-
entiation control pathways may provide novel treatment avenues
for malignant gliomas.
The canonical Wnt cascade is a critical regulator of stem cell
renewal and differentiation in many tissues (Clevers, 2006;
Nusse, 2008; Reya and Clevers, 2005). During normal braindevelopment, Wnt signaling is required for controlling the size
of the self-renewing NSC/progenitor population (Kalani et al.,
2008). Moreover, while attenuation of Wnt signaling causes a
reduction in the NSC/progenitor compartment, its activation
through b-catenin can increase the cycling and expansion of
neural precursors (Chenn and Walsh, 2002; Zechner et al.,
2003), raising the possibility that abnormal Wnt pathway activa-
tion may promote NSC/progenitor transformation. Indeed,
uncontrolled Wnt pathway activation through mutations in APC
(Huang et al., 2000), b-catenin (Zurawel et al., 1998), or axin
(Baeza et al., 2003; Dahmen et al., 2001) has been found in a
subgroup of medulloblastomas, a pediatric brain tumor in the
cerebellum. Although these specific mutations appear to be
rare in gliomas, the level of b-catenin expression appears to be
related to the histological grade in a subset of gliomas (Utsuki
et al., 2002). Sustained b-catenin activation independent of the
mutations has also been demonstrated in a subset of breast,
ovarian, and pancreatic cancers (Bafico et al., 2004; Wang
et al., 2009). In the present study, our findings that PLAGL2
functions to activate Wnt/b-catenin pathway while repression
of Wnt activation in PLAGL2-expressing NSCs sensitize themCancer Cell 17, 497–509, May 18, 2010 ª2010 Elsevier Inc. 505
Figure 8. Model of PlagL2’s Function on
Wnt/b-Catenin Signaling Activation and
NSC Differentiation
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utor to the malignant behavior of at least a subset of malignant
gliomas.
Overall, these data support a model in which PLAGL2
functions primarily to affect gliomagenesis via its impact on
differentiation and self-renewal (Figure 8). In the unstimulated
NSC/progenitor cells lacking PLAGL2 overexpression, the Wnt
receptor complexes are not bound by ligands, allowing the
axin/APC/GSK3b complex to phosphorylate b-catenin and
target it for rapid degradation. When abnormally overexpressed,
PLAGL2 activates Wnt ligand and receptor transcription, result-
ing in the disruption of the axin/APC/GSK3b complex, b-catenin
stabilization, and its subsequent activation. The activated
b-catenin is then transferred into the nucleus and activates its
downstream effectors, which functionally contribute to
PLAGL2-mediated differentiation arrest and self-renewal main-
tenance under differentiation induction. However, it is worth
noting that attenuation of Wnt signaling in PlagL2-expressing
NSCs through either DKK1 overexpression (Figures 7B and 7C)
or Wnt6/Fzd2 knockdown (Figures 7D and 7E) only partially
reverses PlagL2-mediated NSC/progenitor differentiation sup-
pression, suggesting that the combined actions of PLAGL2 at
multiple points in the pathway are needed for full effort and/or
that other differentiation/renewal pathways contribute to regula-
tion of differentiation processes in gliomas.
In summary, aberrant expression of PLAGL2 can function to
sustain normal and neoplastic NSC/progenitor cell renewal and
proliferation under differentiation induction conditions, findings
consistent with the prevailing view that differentiation induction
restrains tumor cell self-renewal and tumorigenic potential
(Pierce and Speers, 1988). Indeed, the differentiation therapy
has contributed significantly to the management of leukemia
(Wang and Chen, 2008). In this regard, one would predict that
a more detailed understanding of the pathways governing self-506 Cancer Cell 17, 497–509, May 18, 2010 ª2010 Elsevier Inc.renewal and/or differentiation of NSCs
and, by extension, GICs would provide
productive entry points for novel drug
development efforts in malignant gliomas
and other cancer types.
EXPERIMENTAL PROCEDURES
Cell Lines and Human Samples
The human glioma cell lines LN215, LN229, A172,
Hs683, LN319, LN340, LNZ308, SF767, U87, and
U343 and the human embryonic kidney cell line
HEK293T were purchased from American Type
Culture Collection. Frozen tumor specimens and
human GIC lines were obtained from the Memorial
Sloan-Kettering Cancer Center tumor bank. All
tumor specimens were collected after obtaining
written informed consent preoperatively. This
study was approved by the Institutional Review
Boards of the Memorial Sloan-Kettering Cancer
Center and Dana-Farber Cancer Institute. TheGICs were generated as described previously (Bao et al., 2006; Lee et al.,
2006; Piccirillo et al., 2006; Singh et al., 2004) without sorting and maintained
as tumor spheres using low-attachment plates in NeuroCult NS-A proliferation
media (human; Stem Cell Technologies) with growth factors. The common
genomic and genetic mutations of the human glioma cell lines and GICs are
included in Table S1.
Mice and Orthotopic Transplants
Primary murine p53/ and Ink4a/Arf/ Pten/ astrocytes were isolated from
5-day-old pups as previously described (Bachoo et al., 2002) and maintained
in DMEM containing 10% FBS. Primary murine wild-type, p53/, and
Ink4a/Arf/ Pten/ NSCs were isolated from the SVZ regions of 1-month-
old mice as previously described (Rietze and Reynolds, 2006; Zheng et al.,
2008) and maintained in NeuroCult NS-A proliferation media (mouse; Stem
Cell Technologies) with growth factors. The orthotopic transplantation was
performed as previously described (Zheng et al., 2008). Animals were followed
daily for development of neurological deficits. All mice experiments were
performed with the approval of the Harvard and Dana-Farber Cancer Institute
Institutional Animal Care and Use Committee.
Antibodies for Immunofluorescence, Immunohistochemistry,
and Western Blot Analysis
The following antibodies were used: GFAP (Dako and BD Biosciences),
human nestin, mouse nestin (Chemicon), Tuj-1 (Covance), S-100 (Lab Vision),
PS-Smad1/5/8, Smad1 (Cell Signaling), CD133 (Miltenyi Biotech), BrdU
(Abcam), HA (Covance), b-catenin, b-actin (Santa Cruz Biotechnology), and
EGFR (Upstate).
Immunostaining
Cells were seeded on polyornithine (Sigma-Aldrich)- and fibronectin (Sigma-
Aldrich)-coated coverslips and cultured within the indicated media. Cells
were fixed with 4% paraformaldehyde and permeabilized with 0.3% Triton
X-100 in PBS and blocked with 1% BSA. Subsequently, samples were
incubated with indicated primary antibodies overnight at 4C and correspond-
ing Alexa Fluor-conjugated secondary antibodies (Invitrogen) 1 hr at room
temperature and mounted with mounting medium with DAPI (Vector). Micro-
scopic images were obtained with a Zeiss LSM 510 confocal microscope in
the Harvard NeuroDiscovery Center optical imaging core, using constant
exposure times for each channel in individual experiments.
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Cell invasion assays were performed in duplicate or triplicate in a Boyden
chamber of 24 well inserts coated with matrix proteins as per the manufac-
turer’s protocol (BD Biosciences). Cells (2 3 105) were washed and then
seeded in serum-free DMEM (Invitrogen). The chemoattractant used was
DMEM + 10% FBS. After 18 hr incubation and removal of the noninvading
cells, the chambers were stained with 0.5% Crystal Violet (Sigma-Aldrich)
for 20 min and the invading cells were counted. Anchorage-independent
growth assays were performed in duplicate or triplicate in 6 well plates. 104
of indicated cells per well were seeded in DMEM + 10% FBS containing
0.4% low-melting agarose on the top of bottom agar containing 1% low-
melting agarose DMEM + 10% FBS. After 14–21 days, colonies were stained
with iodonitrotetrazoliumchloride (Sigma-Aldrich) and counted.
NSC Self-Renewal Assay
NSC self-renewal capacity was measured by plating 100 cells/ml into 6 or 12
well ultra-low cluster plates in NSC proliferation media containing growth
factors (EGF 20 ng/ml and bFGF 10 ng/ml; Sigma-Aldrich) with or without
BMP2 (50 ng/ml; R&D Systems). The number of neurospheres that formed
subsequently per well was quantified after 8 (no BMP2) or 14 days (with
BMP2) and relative sphere formation was plotted versus indicated control.
Expression Profiling and Ingenuity Pathway Analysis
mRNA expression profiling was performed at the Dana-Farber Microarray
Core facility using the Mouse Genome 430 2.0 Array (Affymetrix). Student’s
t test was used to identify differentially expressed genes according to expres-
sion profiles. The ingenuity pathway analysis application was performed to
identify canonical pathways that were most significant to the functionally
related genes according to the manufacturer’s instruction (Ingenuity Systems).
In brief, differentially expressed genes with threshold p% 0.05 were mapped
into Ingenuity Pathways Analysis database as input. Complete profiles are
deposited on the GEO website under super series accession number
GSE21143.
Statistical Analysis
Tumor-free survivals were analyzed using Graphpad Prism4. Statistical
analyses were performed using nonparametric Mann-Whitney test. Compari-
sons of cell growth, self-renewal, and differentiation were performed using the
unpaired Student’s t test. For all experiments with error bars, standard devia-
tion was calculated to indicate the variation within each experiment and data,
and values represent mean ± SEM.
shRNA Sequences
See Supplemental Experimental Procedures for siRNA and shRNA sequences.
ACCESSION NUMBERS
Complete microarray data are deposited on the GEO website under super
series accession number GSE21143.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online at
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